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Abstract
Background: Acute exacerbations contribute to the morbidity and mortality associated with chronic obstructive
pulmonary disease (COPD). This proof-of-concept study evaluates whether intermittent pulsed moxifloxacin
treatment could reduce the frequency of these exacerbations.
Methods: Stable patients with COPD were randomized in a double-blind, placebo-controlled trial to receive
moxifloxacin 400 mg PO once daily (N = 573) or placebo (N = 584) once a day for 5 days. Treatment was repeated
every 8 weeks for a total of six courses. Patients were repeatedly assessed clinically and microbiologically during
the 48-week treatment period, and for a further 24 weeks’ follow-up.
Results: At 48 weeks the odds ratio (OR) for suffering an exacerbation favoured moxifloxacin: per-protocol (PP)
population (N = 738, OR 0.75, 95% confidence interval (CI) 0.565-0.994, p = 0.046), intent-to-treat (ITT) population
(N = 1149, OR 0.81, 95% CI 0.645-1.008, p = 0.059), and a post-hoc analysis of per-protocol (PP) patients with
purulent/mucopurulent sputum production at baseline (N = 323, OR 0.55, 95% CI 0.36-0.84, p = 0.006).
There were no significant differences between moxifloxacin and placebo in any pre-specified efficacy subgroup
analyses or in hospitalization rates, mortality rates, lung function or changes in St George’s Respiratory Question-
naire (SGRQ) total scores. There was, however, a significant difference in favour of moxifloxacin in the SGRQ symp-
tom domain (ITT: -8.2 vs -3.8, p = 0.009; PP: -8.8 vs -4.4, p = 0.006). Moxifloxacin treatment was not associated with
consistent changes in moxifloxacin susceptibility. There were more treatment-emergent, drug related adverse
events with moxifloxacin vs placebo (p < 0.001) largely due to gastrointestinal events (4.7% vs 0.7%).
Conclusions: Intermittent pulsed therapy with moxifloxacin reduced the odds of exacerbation by 20% in the ITT
population, by 25% among the PP population and by 45% in PP patients with purulent/mucopurulent sputum at
baseline. There were no unexpected adverse events and there was no evidence of resistance development.
Trial registration: ClinicalTrials.gov number, NCT00473460 (ClincalTrials.gov).
Background
The morbidity and mortality of chronic obstructive pul-
monary disease (COPD) is substantially contributed to by
frequent acute exacerbations of the disease. Higher
exacerbation rates have been related to a faster decline in
lung function [1-3], and a larger reduction in quality of
life [4]. In addition, mortality has been shown to increase
with frequent, severe exacerbations, particularly if these
require hospitalization [5]. Exacerbations account for
between one-third to one-half of the health economic
burden of COPD [6,7]. Reducing exacerbations is now
one of the goals of COPD maintenance treatment, and
long-acting bronchodilators and inhaled corticosteroids
have been moderately efficacious in this regard [8].
The role of respiratory bacterial pathogens in COPD
has been clarified in recent years. It is likely that 40-50%
of exacerbations are related to bacterial infection, parti-
cularly strains that are new to the patient [9]. This
engenders airway and systemic inflammation that results
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in worsening airway physiology, ultimately manifesting
as respiratory and systemic symptoms [10,11]. The pre-
sence of bacteria in the airways in stable COPD, long
thought to be innocuous, may also contribute to COPD
pathogenesis by causing inflammation and thereby
structural airway damage [12-16].
It is possible, therefore, that reduction of airway bacter-
ial load and/or prevention of new strain acquisition in
COPD patients by the use of antibiotics may reduce the
frequency and severity of exacerbations. Results of pre-
vious trials of prophylactic use of antibiotics in COPD
conducted prior to 1970 demonstrate inconsistent and
small benefits of such therapy. However, these studies
were limited by the small numbers of patients included,
the use of low doses of narrow-spectrum antibiotics, and
by inadequate efficacy assessment [17]. Though widely
used for treatment, respiratory fluoroquinolones have not
been investigated in the prevention of COPD exacerba-
tions. These drugs have several characteristics that make
them attractive as prophylactic agents in COPD, such as
potent in-vitro antimicrobial activity against the major
pathogens in COPD, excellent penetration into respira-
tory tissues, high oral bioavailability, and proven efficacy
in the treatment of exacerbations, including increasing
the exacerbation-free interval [18,19].
Therefore, the PULSE study was conducted to deter-
mine whether intermittent pulsed therapy with the
respiratory fluoroquinolone, moxifloxacin, was more
efficacious than placebo in the reduction of exacerba-
tions of COPD.
Methods
Patients
Stable COPD patients recruited for this study had to be
at least 45 years of age, have smoked for at least 20
pack years, had a ratio of pre-bronchodilator forced
expiratory volume in 1 second (FEV1) to forced vital
capacity (FVC) ≤ 0.70 as well as a percent predicted
forced expiration volume in 1 second (PFEV1) ≤ 80%. In
addition, they had to have chronic bronchitis as defined
by the American Thoracic Society [20] and at least two
exacerbations requiring treatment with antibiotics and/
or oral steroids in the 12 months prior to enrolment.
Further inclusion and exclusion criteria are provided in
Additional file 1: Inclusion and exclusion criteria. Pre-
specified protocol violations resulted in patients being
excluded from the per-protocol (PP) population (see
Additional file 2: Pre-specified protocol violations). The
study was approved by local ethics review committees
and all patients gave written informed consent.
Study design
PULSE was a randomized, double-blind, placebo-con-
trolled, parallel group, multicentre international clinical
trial that was conducted at 76 centres in 15 countries.
Within 1 week of screening, eligible patients were ran-
domly assigned to treatment with either moxifloxacin
400 mg orally once daily for 5 days or matching pla-
cebo for 5 days. Treatment was repeated every 8 weeks
for a total of 6 courses. After randomization, patients
were seen every 8 weeks for clinical evaluation to
record any exacerbations and adverse events, and to
dispense the medication course. Adherence to treat-
ment was assessed by collecting and counting remain-
ing pills at the subsequent study visit. At each visit,
spirometry was performed and disease-related health
status was assessed by using the St George’s Respira-
tory Questionnaire (SGRQ). An end-of-treatment
(EOT) visit was performed at 48 weeks after randomi-
zation. Three additional follow-up visits at 8-weekly
intervals were conducted for a total study duration of
72 weeks.
Clinical laboratory assessments, including blood chem-
istry and haematology, were performed pre-treatment,
24 weeks after randomization, and at the end of
treatment.
Patients were requested to continue with their usual
medication during the study, including long-acting
bronchodilators and inhaled steroids; any adjustment
made to this therapy during the study was one reason
for exclusion from the PP population. Patients were
instructed to continue with study medication in the
event of an exacerbation.
Outcome measurements
The primary efficacy end point was the frequency of
exacerbations during the treatment period, from rando-
mization to the EOT visit at 48 weeks. The primary
definition of exacerbation was an extended definition
added before unblinding to maximize clinically relevant
events. This definition included any confirmed acute
exacerbation of chronic bronchitis (AECB) or uncon-
firmed pneumonia or any other lower respiratory tract
infection (LRTI) with the exception of confirmed pneu-
monia, all requiring intervention (start of systemic anti-
biotic and/or start of systemic steroid and/or
hospitalization within 7 days of the start date of exacer-
bation) and with a minimum of 2 weeks between the
start of two consecutive exacerbations.
The secondary definition included any confirmed
AECB (but excluded confirmed/unconfirmed pneumonia
and any other LRTIs), minimally 2 weeks between start
of two consecutive exacerbations whether or not inter-
vention was documented.
Definitions of AECB and confirmed and unconfirmed
pneumonia are given in Additional file 3: Definitions of
exacerbations.
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Secondary efficacy outcomes included hospitalization
and mortality, changes in disease-related health status
assessed with the SGRQ and changes in lung function
measured as %PFEV1.
Adverse events (coded using the MedDRA system)
and medications were collected at each study visit.
Study staff and patients’ regular physicians were
instructed to treat exacerbations during the study period
with non-fluoroquinolone antibiotics with or without a
short course of oral steroids.
Bacteriological assessments
Sputum samples were collected from all patients at all
clinic visits and were processed locally for Gram stain
and culture. For the following organisms, defined in the
protocol as potential respiratory pathogens in COPD,
moxifloxacin susceptibility testing was performed locally
by E-test: Haemophilus influenzae, Haemophilus parain-
fluenzae, Streptococcus pneumoniae, Moraxella catar-
rhalis, Klebsiella pneumoniae, Pseudomonas aeruginosa,
and Staphylococcus aureus.
Monitoring of changes in gastrointestinal flora was
conducted by collecting rectal swabs from a subgroup of
211 patients in 23 sites at baseline, week 24, week 48
(EOT), and week 72. Staphylococcus spp., Escherichia
coli, Enterococcus spp., Enterobacter spp., K. pneumo-
niae, P. aeruginosa and Candida spp. were isolated from
the rectal swab cultures. All bacterial isolates were pro-
cessed locally and then transported to a central labora-
tory where isolates were re-identified and the minimum
inhibitory concentrations (MIC) to a range of antibiotics
were determined by broth microdilution, according to
Clinical Laboratory Standards Institute (CLSI)
recommendations.
Analysis populations
This trial was designed as a proof-of-concept study to
test whether long-term intermittent treatment with an
antibiotic would reduce exacerbation frequency in
patients with COPD. To avoid potential dilution of the
definitive efficacy results, the primary population for
efficacy analyses was the PP population, as defined in
Additional file 4: Statistical analysis. Analyses in the
intent-to-treat (ITT) population, randomized patients
who received at least one dose of study medication,
were supportive.
Pre-specified patient subgroups for analysis included
those with: use of inhaled steroids at any time during
the study; use of systemic steroids at any time during
the study; use of long-acting bronchodilators at any
time during the study; past smokers at baseline; current
smokers at baseline; patients with a baseline 50 < %
PFEV1 ≤ 80; patients with a baseline 30 < %PFEV1 ≤ 50;
patients with a baseline %PFEV1 ≤ 30; patients with
medication violations during the 48-72-week period of
the study. Post-hoc subgroup analyses of patients with
mucopurulent/purulent sputum and those without
mucopurulent/purulent sputum at baseline were also
carried out. The assessment of sputum purulence was
made by the investigator based on patient report of col-
our of sputum.
Statistical analysis
Continuous demographic variables were analysed using
two-way analysis of variance (ANOVA) and categorical
demographic variables by a Cochran-Mantel-Haenszel
test. A p-value of < 0.05 was considered significant.
Further information on statistical analysis is given in the
Additional file 4: Statistical analysis.
The primary efficacy variable was the number of
exacerbations recorded after 48 weeks of intermittent
pulsed therapy. Numbers of exacerbations were grouped
into four categories: 0, 1, 2, and ≥ 3, and a pre-specified
logistic regression model was used to test the null
hypothesis that the number of exacerbations in the
moxifloxacin group was not different from the number
of exacerbations in the placebo group. Odds ratios,
adjusted for region and %PFEV1, were calculated for the
mean rate of exacerbations. The absolute risk reduction
was also tested, to calculate the number of patients
needed to treat (NNT) to prevent one exacerbation.
Secondary efficacy outcomes were analysed as fol-
lows. Hospitalization and mortality were analysed by
Fisher’s exact test. Responses to the SRGQ were ana-
lysed using an analysis of covariance (ANCOVA)
model, with the null hypothesis of no change in total
SGRQ score between baseline and EOT, and adjusted
for geographical region, SGRQ total score at baseline,
sex, age, and treatment. Changes in lung function
measured by %PFEV1 were analysed using a repeated
measures ANOVA adjusted for region, visit, treatment
group, and the interaction term between treatment
and visit.
Results
Study population
A CONSORT flow diagram charts the disposition of
patients throughout the study (Figure 1). A total of 1404
eligible patients were enrolled. Of these, 1157 were ran-
domized to either moxifloxacin (N = 573) or placebo
(N = 584). Four patients in each group did not receive
the study drug, leaving 569 and 580 patients in the ITT
population for moxifloxacin and placebo, respectively.
The primary analysis population was PP EOT, for which
351 and 387 patients in the moxifloxacin- and placebo-
treated groups were eligible. Reasons for exclusion from
the PP EOT population were similar between the moxi-
floxacin and placebo treatment arms (Figure 1).
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Demographic and baseline clinical characteristics of the
ITT and PP EOT populations are shown in Additional
file 5: Demographic, clinical and medical characteristics
at baseline. There were no statistically significant differ-
ences in baseline characteristics between the ITT and
PP EOT populations, or between patients randomized to
moxifloxacin or placebo. Premature terminations during
the 48-week study period were more frequent in the
moxifloxacin group (n = 102, 17.8%) than in the com-
parator group (n = 78, 13.4%) (p = 0.036). The main
reason for premature discontinuation was consent with-
drawal in both treatment arms (n = 33, 5.8% and n =
28, 4.8% in the moxifloxacin- and placebo-treated
patients, respectively).
Frequency of exacerbations
Overall population
Figures 2A and 2B illustrate the distribution of the
number of exacerbations for the PP EOT and the ITT
populations, respectively. In the PP EOT population,
moxifloxacin reduced the likelihood of having an
exacerbation by 25%. The mean rate of exacerbations
was 0.88 (SD 1.24) in the placebo group and 0.75 (SD
1.15) in the moxifloxacin group, which resulted in a
common odds ratio (OR) of 0.75 (95% confidence
interval (CI) 0.57-0.99), and shows a statistically signif-
icant reduced odds for suffering an exacerbation with
moxifloxacin treatment vs placebo (p = 0.046) (Figure
3a). At EOT there was an absolute risk reduction of
Figure 1 Progression of patients through the study.
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Figure 2 Frequency distribution of exacerbations. Data are after 48 weeks of intermittent therapy in (a) the per-protocol end-of-treatment
(PP EOT) population and (b) the intent-to-treat (ITT) population.
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Figure 3 Clinical efficacy of moxifloxacin vs placebo. (a) Per-protocol end-of-treatment (PP EOT) and intent-to-treat (ITT) populations
according to the primary and secondary definitions of an exacerbation, and (b) patients with purulent/mucopurulent sputum at baseline (PP
EOT and ITT populations using the primary definition of an exacerbation). The first set of p-values on the graphs are from logistic regression
analysis using the median value for patients missing at 48 weeks. Corresponding p-values for logistic regression analysis using last observation
carried forward are given in brackets. AECB, acute exacerbation of chronic bronchitis.
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5.5% for exacerbations experienced during the 48-week
study period. The NNT to prevent one exacerbation is
19. The reduction in exacerbations was similar when
the secondary definition of exacerbation was applied.
The mean (SD) rate of exacerbations was 0.96 (1.26) in
the placebo group and 0.81 (1.16) in the moxifloxacin
group, with an OR of 0.73 (95% CI 0.56-0.97; p =
0.028). The absolute risk reduction in the number of
exacerbations experienced during the 48-week study
period was 5.7% and the NNT to prevent one exacer-
bation was 18.
In the ITT population the mean (SD) rate of
exacerbations (primary definition) was 0.94 (1.24) vs
0.88 (1.29) for placebo and moxifloxacin, respectively.
Moxifloxacin reduced the likelihood of having an
exacerbation by 19%, with an OR of 0.81 (95% CI
0.65-1.01; p = 0.059). The absolute risk reduction in
exacerbations was 3.6 and the NNT was 28. A statisti-
cally significant difference in the reduction in the
odds for experiencing an exacerbation with moxifloxa-
cin was seen with the secondary definition (mean
[SD] rate of exacerbations 1.04 [1.29] placebo, 0.94
[1.30] moxifloxacin; OR 0.77, 95% CI 0.61-0.95; p =
0.017) (Figure 3a). The absolute risk reduction for
exacerbation was 4.9% and the NNT was 21. A trend
for greater time to first exacerbation was seen for
moxifloxacin- vs placebo-treated patients in both the
PP EOT and ITT populations, although this did not
reach statistical significance (p = 0.051 and 0.062
respectively) (see Additional file 6: Additional results,
Figure S1).
Subgroup analyses
Predefined efficacy subgroups
The ORs achieved for most of the predefined efficacy
subgroups were similar to those for the overall PP and
ITT populations (see Additional file 6: Additional
results, Table S1). There were no significant differences
between moxifloxacin and placebo in any of the efficacy
subgroups in either the PP EOT or the ITT populations.
Patients with mucopurulent/purulent sputum
Post-hoc analysis of PP EOT patients (167 moxifloxacin,
156 placebo) who had mucopurulent/purulent sputum
at baseline showed that in these patients moxifloxacin
reduced the likelihood of exacerbations (primary defini-
tion) by 45% (mean [SD] rate of exacerbations: placebo
1.04 [1.29], moxifloxacin 0.79 [1.28]; OR 0.55; 95% CI
0.36-0.84; p = 0.006) (Figure 3b). For this subgroup, the
absolute risk reduction in exacerbations was 14.4% and
the NNT to prevent one exacerbation is 7. The reduc-
tion in odds of having an exacerbation was also signifi-
cant when using the secondary definition: the mean
(SD) rate of exacerbations was 1.11 (1.29) for placebo vs
0.84 (1.31) for moxifloxacin, resulting in an OR of 0.53
(95% CI 0.35-0.82; p = 0.004). This corresponds to a
15.2% absolute risk reduction in exacerbations and an
NNT of 7. In the ITT population with mucopurulent/
purulent sputum, the reduction in the odds of having an
exacerbation with moxifloxacin was not statistically sig-
nificant (Figure 3B).
Patients with non-mucopurulent/purulent sputum
Post-hoc analysis of PP EOT patients without muco-
purulent/purulent sputum at baseline (n = 415, 184
moxifloxacin, 231 placebo) showed the mean (SD) rate
of exacerbations using the primary definition was 0.77
(1.20) and 0.73 (1.02) for placebo and moxifloxacin,
respectively, resulting in an OR of 0.96 (95% CI 0.66-
1.40; p = 0.83). Similar results were seen using the sec-
ondary definition, where the mean (SD) rate of exacer-
bations was 0.86 (1.3) for placebo and 0.79 (1.02) for
moxifloxacin resulting in an OR of 0.94 (95% CI 0.65-
1.37; p = 0.76). In the ITT population without purulent/
mucopurulent sputum, the reduction in the odds of hav-
ing an exacerbation with moxifloxacin was also not sta-
tistically significant.
Secondary efficacy results
Hospitalizations and mortality
The overall hospitalization rate in the PP EOT popula-
tion was similar for moxifloxacin and placebo: 56/351
(15.9%) and 54/387 (14.0%), respectively (p = 0.80). In
the ITT population there were more patients hospita-
lized in both groups (moxifloxacin: 131/569, 23.0%; pla-
cebo: 136/580, 23.4%), but this did not differ
significantly between treatments. In addition, there were
no statistically significant differences in frequency of
hospitalization between the moxifloxacin- and placebo-
treated groups of patients in either the PP EOT or the
ITT populations, for the subgroups of COPD and LRTI-
related hospitalizations, pneumonia-related hospitaliza-
tions or AECB-related hospitalizations (see Additional
file 6: Additional results, Table S2).
The mortality rate during the 48 weeks of the study
was low. In the PP EOT population there was 1/351
(0.3%) death in the moxifloxacin group and 3/387 (0.8%)
deaths in the placebo group (see Additional file 6: Addi-
tional results, Table S2). Corresponding numbers for the
ITT population were 15/569 (2.6%) in the moxifloxacin
group and 17/580 (2.9%) in the placebo group. There
were no significant differences in mortality rates
between moxifloxacin and placebo in either population
or any subgroup.
Lung function
Average lung function declined slightly during the study
in both groups of patients. Lung function changes were
similar for the moxifloxacin and placebo groups in both
the ITT and PP EOT populations (see Additional file 6:
Additional results, Tables S3 and S4).
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Health status
Total scores on the SGRQ improved from baseline for
both moxifloxacin and placebo. At Week 48 in the PP
EOT population, the mean change from baseline total
SGRQ score was -4.8 for moxifloxacin and -3.5 for pla-
cebo (p = 0.33) (see Additional file 6: Additional results,
Table S5). Corresponding values in the ITT population
were -4.0 for moxifloxacin and -2.8 for placebo (p = 0.29).
The SGRQ domain scores of symptoms, activity and
impact were also assessed (see Additional file 6: Addi-
tional results, Table S6). Categorical responder analysis
of the SGRQ symptom domain scores showed a statisti-
cally significant difference in favour of moxifloxacin in
the number of patients showing at least a 4-point
improvement and at least an 8-point improvement
in both the PP EOT and ITT populations (p ≤ 0.01)
(Figure 4). Moxifloxacin treatment did not result in sig-
nificant improvement in the activity or impact
subscores.
Baseline bacteriology
Sputum isolates
Relevant respiratory pathogens were isolated at rando-
mization from about 24% of all patients. The most com-
mon potential COPD pathogens in both the
moxifloxacin and placebo groups were H. influenzae, H.
parainfluenzae, and S. pneumoniae isolated from 8.3%,
6.6%, and 4.3% of the PP EOT population, respectively.
S. aureus, P. aeruginosa, M. catarrhalis, and K. pneumo-
niae were isolated less frequently (from 2.6%, 2.4%,
2.0%, and 2.0%, of the PP EOT population, respectively).
Over the course of the 48-week treatment period,
there was a trend towards a reduction in the total num-
ber of patients with pathogens isolated, which was more
pronounced with moxifloxacin than placebo (data not
shown, manuscript in preparation). Intermittent treat-
ment with either moxifloxacin or placebo did not cause
sustained MIC increases. The median MIC for moxiflox-
acin for H. influenzae, H. parainfluenzae, M. catarrhalis,
K. pneumoniae, S. pneumoniae and S. aureus did not
change or changed little during the study in both the
placebo and moxifloxacin groups (Figure 5 and Addi-
tional file: Additional results, Table S7). In the moxiflox-
acin-treated group, one S. pneumoniae isolate resistant
to moxifloxacin (MIC 4 mg/L) was isolated from a
patient in the moxifloxacin arm on the sixth scheduled
visit (Week 40); this strain was not associated with an
exacerbation and did not persist at subsequent visits.
For S. aureus, one to three moxifloxacin-resistant iso-
lates were detected at baseline and at different points in
the study; these isolates were not associated with exacer-
bations and did not persist. The median MIC of moxi-
floxacin against P. aeruginosa isolates increased to 4
mg/L at Week 24, but decreased to 1 mg/L by EOT,
returning to value at randomization in the moxifloxacin
group. In the placebo group, the median MIC of moxi-
floxacin against P. aeruginosa isolates increased from 0.5
mg/L at randomization to 2 mg/L by EOT.
Rectal isolates
For the monitored pathogens Staphylococcus spp., E.
coli, Enterococcus spp., Enterobacter spp., K. pneumo-
niae, and P. aeruginosa isolated from the rectal swabs,
Figure 4 Changes in St George’s Respiratory Questionnaire symptom subscale scores. (a) Per-protocol end-of-treatment (PP EOT)
population using a minimum clinically important difference (MCID) of 4 units; (b) PP EOT population using an MCID of 8 units; (c) intent-to-treat
(ITT) population using an MCID of 4 units; (D) ITT population using an MCID of 8 units.
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no consistent major change in the median moxifloxacin
MIC was detected in either treatment arm.
Safety
Adverse events
The overall incidence of adverse events was similar in
the moxifloxacin- (82.1%) and placebo-treated (85.0%)
ITT/safety populations (Table 1). Treatment-emergent,
drug-related adverse events were significantly higher
with moxifloxacin as were premature discontinuations
due to an adverse event, largely due to an excess of gas-
trointestinal disorders. The most common adverse
events (occurring in ≥ 2 patients) leading to premature
discontinuation of treatment, included nausea (moxiflox-
acin 5 vs placebo 0), vomiting (4 vs 0), diarrhoea (3 vs
1), hypersensitivity (2 vs 0), dyspnoea (2 vs 0), urticaria
(2 vs 0) and upper abdominal pain (0 vs 2). One case of
diarrhoea caused by Clostridium difficile was reported in
the placebo group.
Discussion
Intermittent prophylactic pulsed treatment with moxi-
floxacin resulted in a 19% reduction in the odds of
exacerbation in the ITT population and a 25% reduction
in the PP EOT population in this study. This corre-
sponds to NNTs of 28 and 19, respectively. Pre-specified
subgroup analyses demonstrated that the reduction in
exacerbations with moxifloxacin was seen in COPD of
all severity categories, among smokers and ex-smokers,
and in patients receiving concomitant COPD treatments
including inhaled steroids and long-acting bronchodila-
tors. In a post-hoc analysis, a larger (45%) reduction in
the odds of exacerbation, corresponding to an NNT of
7, was seen among patients who reported purulent/
mucopurulent sputum at baseline. The extent of reduc-
tion in exacerbations in these patients is similar to that
seen with long-acting bronchodilators and inhaled ster-
oids in recent clinical trials in COPD [21-26]. In a study
with bronchoscopic sampling, sputum purulence was
shown to be a reliable indicator of significant bronchial
infection in patients with exacerbations of COPD [27].
It is possible that sputum purulence is also a marker for
chronic bronchial infection in stable COPD, thereby
explaining the greater benefit with prophylactic antibio-
tic treatment in these patients.
Intermittent moxifloxacin did not significantly improve
overall health status, reduce rates of hospitalization or
mortality, or slow the ongoing decline in lung function in
COPD. The size and duration of the study were not ade-
quate for these secondary end points. In the patient
population recruited in this study, hospitalization and
mortality rates were low, making it difficult to observe a
Figure 5 Median MIC for moxifloxacin for Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus and Pseudomonas
aeruginosa. Data are shown for the entire 72 weeks of the study: 48 weeks of intermittent therapy and 24 weeks of follow-up. S, screening visit;
R, randomization visit; EOT, end-of-treatment visit; MIC, minimum inhibitory concentration; numbers in the table are of patients with an isolate at
a given time point.
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difference between the two treatment groups. In terms of
lung function, it is, perhaps, ambitious to expect
improvements in underlying COPD in such a relatively
short study of only six 5-day courses of an antibiotic.
There were more adverse events with moxifloxacin
than with placebo, however, the overall levels of drug-
related adverse events were low in both groups (9.3%
with moxifloxacin and 3.8% with placebo) and compar-
able to findings in another large study with moxifloxacin
in AECOPD [18]. The most common treatment-related
adverse events related to the gastrointestinal tract,
which also resulted in more premature terminations
(3.6% vs 1.8%, in the moxifloxacin- and placebo-treated
groups, respectively; p = 0.07). C. difficile infection was
not reported in any of the patients taking moxifloxacin.
A major concern with antibiotic use is the emergence
of resistant organisms. Regular monitoring of sputum
flora and, in a subgroup, of faecal flora was therefore an
essential part of the PULSE study. There was a transient
increase in MIC of one strain of S. pneumoniae and
three isolates of S. aureus. However, these isolates did
not persist or cause exacerbations, and resistance emer-
gence was not seen among patients in either moxifloxa-
cin or placebo arms. The dosing regimen in PULSE was
based on pharmacodynamic/pharmacokinetic principles,
with intermittent dosing of a potent antibiotic at full
doses, rather than use of therapeutic or subtherapeutic
doses for prolonged periods. We speculate that such a
dosing regimen was related to the lack of resistance
emergence seen in this study although longer periods of
observation are needed to confirm this. Patients who
had colonization of moxifloxacin-resistant P. aeruginosa
at baseline were excluded from this study but those with
P. aeruginosa sensitive to moxifloxacin were included.
The detection of P. aeruginosa with a higher MIC dur-
ing the study than those present at screening/randomi-
zation suggests that patients colonized by this organism
in the airway should not be considered for the therapeu-
tic regimen described in this study. Further long-term
studies are required to determine whether this type of
intermittent preventive antibiotic therapy circumvents
the development of resistant organisms.
Table 1 Incidence of adverse events (intent-to-treat (ITT)/safety population).
Moxifloxacin
(N = 569)
n (%)
Placebo
(N = 580)
n (%)
p-value*
Any adverse event 467 (82.1) 493 (85.0) 0.181
Any treatment-emergenta adverse event 258 (45.3) 265 (45.7) 0.906
Any treatment-emergenta drug-related adverse eventsb 53 (9.3) 22 (3.8) < 0.001
Cardiac disorders 3 (0.5) 1 (0.2)
Gastrointestinal disorders 27 (4.7) 4 (0.7)
Diarrhea 17 (3.0) 9 (1.6)
Nausea 6 (1.1) 0 (-)
Vomiting 5 (0.9) 1 (0.2)
General disorders and administration site conditions 4 (0.7) 2 (0.3)
Asthenia 3 (0.5) 0 (-)
Immune system disorders 4 (0.7) 0 (-)
Hypersensitivity 3 (0.5) 0 (-)
Infections and infestations 5 (0.9) 3 (0.5)
Musculoskeletal and connective tissue disorders 3 (0.5) 1 (0.2)
Nervous system disorders 6 (1.1) 4 (0.7)
Dizziness 3 (0.5) 1 (0.2)
Respiratory, thoracic and mediastinal disorders 8 (1.4) 0 (-)
Dyspnea 4 (0.7) 0 (-)
Skin and subcutaneous tissue disorders 5 (0.9) 5 (0.9)
Deaths 15 (2.6) 17 (2.9)
Any treatment-emergenta serious adverse event 94 (16.5) 97 (16.7) 0.926
Any treatment-emergenta drug-related serious adverse event 9 (1.6) 3 (0.3) 0.076
Any adverse event leading to premature discontinuation 26 (4.6) 16 (2.8) 0.102
Any deaths 19 (3.3) 26 (4.5) 0.318
aEvents were determined to be treatment-emergent if they started after initiation of study medication up to 7 days post-therapy for each pulse of study
medication
bIndividual events listed under treatment-emergent drug-related adverse events occurring in ≥ 0.5% of subjects in either treatment group
*Post-hoc unadjusted Chi-squared test
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There are three main limitations of the present study.
The first is that there were fewer than expected exacer-
bations, despite the use of a wider definition of an
exacerbation to maximize the number of events; only
0.88 were reported in the placebo group compared with
the predicted 1.4 exacerbations per patient during the
48-week study period, with approximately 50% of the
placebo group experiencing no exacerbations during 48
weeks. This ‘placebo’ effect of reduced exacerbations has
been observed in other clinical trials and is probably
related to closer monitoring and better compliance with
maintenance COPD treatments [26]. Secondly, mainte-
nance therapies for COPD, such as long-acting broncho-
dilators and inhaled steroids, which could affect
frequency of exacerbations, were not standardized across
all patients in this study. However, the frequency of
such treatments did not differ between the treatment
arms and benefit with moxifloxacin was seen in sub-
groups receiving such concomitant treatment. Finally, it
is possible that some exacerbations were unreported due
to the absence of daily monitoring [4,28].
The use of inhaled steroid and long-acting bronchodi-
lators, both anticholinergic and beta-agonists, does
result in a reduction in exacerbations. However, in a
recent trial, when inhaled salmeterol/fluticasone was
added to tiotropium, there was no additional reduction
in frequency of exacerbations [29]. Current optimal
therapy for COPD often does not result in an exacerba-
tion-free patient. Increased incidence of pneumonia with
inhaled steroids is an adverse effect when these drugs
are used to reduce exacerbations [22,30,31]. Alternative
approaches to reducing exacerbations are therefore
required in some patients with COPD.
Conclusions
Prevention of acute and chronic infection in COPD
would be best achieved by augmenting the innate and
adaptive immune responses with vaccines and novel
drugs. Until this is possible, treatment with intermittent
pulsed moxifloxacin could be indicated in certain sub-
groups of patients. Such patients include those with
baseline purulent/mucopurulent or purulent sputum
production, who are not colonized by P. aeruginosa, and
who have an unacceptable frequency of exacerbations in
spite of maximal therapy with inhaled agents for COPD
or who experience complications such as pneumonia
with these treatments. Though PULSE demonstrates
that intermittent treatment with moxifloxacin is an
effective option for preventing acute exacerbations in
patients with COPD, further studies are required to
determine the optimal patient population as well as dos-
ing regimen and therapy duration for this approach.
Additional file 1: Inclusion and exclusion criteria. List of criteria used
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Additional file 6: Additional results. Figure S1. Time to first
exacerbation in (a) the PP EOT population and (b) the ITT population.
Dropouts were treated as censored. PP EOT, per-protocol end-of-
treatment; ITT, intent-to-treat. Table S1. Analysis of pre-specified
subgroups. Data show number of exacerbations by the end of treatment
in the per-protocol end-of-treatment (PP EOT) and intent-to-treat (ITT)
populations. Table S2. Frequency of hospitalization and mortality. Data
are shown for moxifloxacin- and placebo-treated patients, for the per-
protocol end-of-treatment (PP EOT) and intent-to-treat (ITT) populations
from Week 0 to Week 48. Table S3. Lung function. Data show the
percentage predicted FEV1 during the 48 weeks of treatment with
moxifloxacin or placebo in the per-protocol end-of-treatment (PP EOT)
and intent-to-treat (ITT) populations. Table S4. Changes in lung function.
Values are adjusted mean change of percentage predicted FEV1 over
time in the per-protocol end-of-treatment (PP EOT) and intent-to-treat
(ITT) populations. Table S5. Change from baseline in St George’s
Respiratory Questionnaire (SGRQ) total scores. Scores are shown for each
visit for those patients in the per-protocol end-of-treatment (PP EOT) and
intent-to-treat (ITT) populations who provided SGRQ data. Table S6.
Changes in St George’s Respiratory Questionnaire (SGRQ) symptom
scores. Values show change from baseline to Week 48 in activity and
impact subscores for the per-protocol end-of-treatment (PP EOT) and
intent-to-treat (ITT) populations Table S7. Median moxifloxacin minimum
inhibitory concentrations (MIC50). Values are MICs (numbers) for bacteria
isolated from the sputum and rectal swab samples of moxifloxacin- or
placebo-treated patients in the per-protocol end-of-treatment (PP EOT)
population at each study visit.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1465-9921-11-
10-S6.DOC ]
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